📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Suraksha Diagnostic Group CFO K S Ravindra Resigns Effective May 31, 2026
Suraksha Diagnostic Limited has announced the resignation of Mr. K S Ravindra from the post of Group Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The resignation was tendered on March 2, 2026, citing personal reasons, with his tenure concluding on May 31, 2026. The company has initiated a three-month notice period to ensure a smooth transition of financial responsibilities. No material reasons other than personal ones were cited for the departure.
Key Highlights
Mr. K S Ravindra resigned as Group CFO and KMP on March 2, 2026
The resignation is effective from the close of business hours on May 31, 2026
A 3-month notice period is being served to facilitate a smooth leadership transition
The outgoing CFO confirmed there are no material reasons for resignation other than personal ones
💼 Action for Investors
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure continuity in financial management. The three-month notice period provides a reasonable window for a stable transition.
Suraksha Diagnostic Q3 Revenue Jumps 30% YoY to ₹78.3 Cr; EBITDA Margins at 30.6%
Suraksha Diagnostic reported a strong 30.3% YoY increase in Q3 FY26 revenue to INR 783.09 million, driven by volume expansion and a shift towards high-value genomic testing. While EBITDA grew 26.1% to INR 237.82 million, margins saw a temporary compression to 30.6% due to pre-operative costs associated with 24 new centers. The company served 0.36 million patients in Q3, a 23% increase, while the total number of tests performed rose by 30.7% to 2.06 million. Management revised EBITDA margin guidance slightly downward to approximately 32% for the full year, citing aggressive network expansion and seasonal weakness.
Key Highlights
Q3 FY26 revenue grew 30.3% YoY to INR 783.09 million, with 9M FY26 revenue up 21.86% to INR 2,313.81 million
EBITDA margin for Q3 stood at 30.6%, impacted by 24 new centers, while 42 mature centers maintain robust profiles
The new genomics vertical Suraksha Sutra is generating a monthly revenue run rate of approximately INR 2.1-2.2 million
The company remains net debt positive with a cash position of approximately INR 29 crores as of the reporting date
Expansion continues with 12 centers commissioned in 9 months and 6 more facilities currently in the execution phase
💼 Action for Investors
Investors should focus on the successful ramp-up of new centers and the high-margin genomics vertical, which act as long-term growth drivers despite short-term margin compression. Monitor the stabilization of EBITDA margins as the 24 new centers reach maturity over the next 12-18 months.
Suraksha Diagnostic Q3 Revenue Jumps 30% to ₹783 Mn; Mature Center Margins Hit 36.2%
Suraksha Diagnostic reported a robust 30.3% YoY revenue growth in Q3 FY26, reaching ₹783.09 million, driven by aggressive network expansion. While overall EBITDA margins compressed slightly to 30.6% due to pre-operative costs of 24 new centers, mature centers (over 2 years old) continue to deliver strong margins of 36.2%. The company is diversifying into high-value segments like Genomics and Fetal medicine to increase revenue per patient, which rose to ₹2,140. Management remains focused on 'Investing for Scale,' with 6 more centers planned for launch in Q4 FY26.
Key Highlights
Q3 FY26 Revenue increased 30.3% YoY to ₹783.09 million, while PAT grew 21% to ₹72.41 million.
Mature centers (42 units) operate at a 36.2% EBITDA margin, while 24 new centers are currently at -12.5% during their gestation period.
Total network reached 66 diagnostic centers and 173 collection centers as of December 31, 2025.
Revenue per patient improved to ₹2,140 in 9M FY26, supported by the launch of the high-margin Suraksha Genomics vertical.
EBITDA for 9M FY26 stood at ₹734.04 million, representing a 12.8% YoY growth despite heavy investment in expansion.
💼 Action for Investors
Investors should monitor the margin trajectory as the 24 recently opened centers mature; their shift toward the 36% margin profile of established centers will be the primary driver for future earnings upgrades. The successful scaling of the specialized Genomics vertical remains a key long-term catalyst for valuation re-rating.
Suraksha Diagnostic Q3 FY26 Income Up 30.3% to ₹783M; Test Volumes Surge 30.7%
Suraksha Diagnostic Limited reported robust Q3 FY26 results with total income rising 30.3% YoY to ₹783.09 million. Net profit increased by 21% to ₹72.41 million, while EBITDA grew 26.1% to ₹237.82 million. The company witnessed significant volume growth with total tests increasing by 30.7% YoY to 2.06 million. Although EBITDA margins compressed slightly to 30.6% due to aggressive expansion, mature centers continue to deliver strong 37% margins.
Key Highlights
Total Income grew 30.3% YoY to ₹783.09 million in Q3 FY26.
EBITDA increased by 26.1% YoY to ₹237.82 million with a 30.6% margin.
Total test volume rose 30.7% YoY to 2.06 million; patients served grew 23% to 0.36 million.
Average Revenue per Patient (ARPP) increased 6.1% YoY to ₹2,181.
Added 12 new centers in 9M FY26 with 6 more currently under development.
💼 Action for Investors
The stock remains attractive due to strong volume growth and the high-margin potential of mature centers (37%). Investors should watch for margin recovery as the 12 newly added centers scale up over the next 12-18 months.
Suraksha Diagnostic Q3 FY26 Standalone PAT Rises to ₹9.75 Crore, Income Up 20% YoY
Suraksha Diagnostic Limited reported a steady growth in its standalone operations for the quarter ended December 31, 2025. Total standalone income reached ₹58.30 crore, representing a 20.7% increase compared to the ₹48.29 crore reported in the same quarter last year. Standalone Net Profit for the quarter stood at ₹9.75 crore, while consolidated performance was slightly impacted by losses in subsidiaries totaling ₹0.91 crore. The company is also managing a legal dispute in Meghalaya involving ₹4.35 crore in receivables and investments.
Key Highlights
Standalone Total Income grew 20.7% YoY to ₹58.30 crore from ₹48.29 crore in Q3 FY25.
Standalone Profit After Tax (PAT) for Q3 FY26 stood at ₹9.75 crore with an EPS of ₹1.25.
Consolidated subsidiaries contributed ₹2.83 crore in revenue but reported a net loss of ₹0.91 crore for the quarter.
Nine-month (9M FY26) standalone total income reached ₹163.30 crore compared to ₹143.30 crore in the previous year.
Management is monitoring a ₹4.35 crore dispute regarding a step-down subsidiary's operations in Meghalaya.
💼 Action for Investors
The core standalone diagnostic business shows robust double-digit growth and healthy profitability. Investors should monitor the turnaround of loss-making subsidiaries and the resolution of the Meghalaya legal dispute which involves significant receivables.